The stock of Sage Therapeutics Inc (SAGE) has gone up by 1.32% for the week, with a 34.31% rise in the past month and a 38.14% rise in the past quarter. The volatility ratio for the week is 1.13%, and the volatility levels for the past 30 days are 2.16% for SAGE. The simple moving average for the past 20 days is 5.81% for SAGE’s stock, with a 31.42% simple moving average for the past 200 days.
Is It Worth Investing in Sage Therapeutics Inc (NASDAQ: SAGE) Right Now?
The stock has a 36-month beta value of 0.26. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 2 as “overweight,” 15 as “hold,” and 0 as “sell.”
The public float for SAGE is 55.09M, and at present, short sellers hold a 9.53% of that float. On July 10, 2025, the average trading volume of SAGE was 1.59M shares.
SAGE) stock’s latest price update
The stock price of Sage Therapeutics Inc (NASDAQ: SAGE) has surged by 0.44% when compared to previous closing price of $9.16, but the company has seen a 1.32% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-01 that NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) — Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Sage Therapeutics, Inc. (NASDAQ: SAGE ) related to its sale to Supernus Pharmaceuticals, Inc. Upon completion of the proposed transaction, current Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable (i) $0.50 the first commercial sale of the drug Zurzuvae in Japan to third-aprty consumers following regulatory approval on or before June 30, 2026; (ii) $1.00 when net sales of Zurzuvae reach or exceed $300 million in the U.S. on or before December 31, 2028; and (iii) $1.00 when net sales of Zurzuvae reach or exceed $375 million in the U.S. on or before December 31, 2030. Is it a fair deal?
Analysts’ Opinion of SAGE
Many brokerage firms have already submitted their reports for SAGE stocks, with BofA Securities repeating the rating for SAGE by listing it as a “Underperform.” The predicted price for SAGE in the upcoming period, according to BofA Securities is $5 based on the research report published on March 11, 2025 of the current year 2025.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see SAGE reach a price target of $4. The rating they have provided for SAGE stocks is “Sector Perform” according to the report published on November 21st, 2024.
SAGE Trading at 21.39% from the 50-Day Moving Average
After a stumble in the market that brought SAGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.70% of loss for the given period.
Stock Fundamentals for SAGE
Current profitability levels for the company are sitting at:
- -8.06 for the present operating margin
- 0.81 for the gross margin
The net margin for Sage Therapeutics Inc stands at -7.48. The total capital return value is set at -0.91. Equity return is now at value -63.53, with -57.29 for asset returns.
Based on Sage Therapeutics Inc (SAGE), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -26.24.
Currently, EBITDA for the company is -409.49 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 11.45. The receivables turnover for the company is 4.42for trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.13.
Conclusion
To sum up, Sage Therapeutics Inc (SAGE) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
